Drug intelligence / Profile preview

rabeprazole + colloidal pectin bismuth + amoxicillin + clarithromycin

Development stage
Phase 4
Lead developer
Eisai
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

This appears to be a quadruple therapy regimen used for Helicobacter pylori (H. pylori) eradication. The combination includes a proton pump inhibitor (rabeprazole), a bismuth compound (colloidal pectin bismuth), and two antibiotics (amoxicillin and clarithromycin). ## Description This is a bismuth-containing quadruple therapy used for the eradication of Helicobacter pylori infection. The combination works through multiple mechanisms: - Rabeprazole reduces stomach acid production, creating a less acidic environment that inhibits H. pylori growth and enhances antibiotic efficacy[4][10] - Bismuth compounds have direct antimicrobial effects against H. pylori and help prevent antibiotic resistance[5][8] - Amoxicillin disrupts bacterial cell wall synthesis[4][6] - Clarithromycin inhibits bacterial protein synthesis[4][6] This combination is particularly valuable in areas with high antibiotic resistance rates, as the bismuth component helps overcome resistance issues. Clinical trials have shown high eradication rates with this type of quadruple therapy, typically administered for 10-14 days[1][6].

02

Targets

H. pylori 50S subunit (Helicobacter pylori 50S ribosomal subunit)ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on rabeprazole + colloidal pectin bismuth + amoxicillin + clarithromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabeprazole + colloidal pectin bismuth + amoxicillin + clarithromycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call